Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients …

Obesity is one of the major risk factors for the development of both impaired glucose
tolerance (IGT, or prediabetes) and type 2 diabetes (T2D), and its prevalence worldwide …

Abstract Sodium–glucose cotransporter 2 (SGLT-2) inhibitors (i) reduce cardiovascular and
renal events in patients with and without type 2 diabetes (T2D). However, the underlying …

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are new oral drugs for the therapy of
patients with type 2 diabetes mellitus (T2DM). Research in the past decade has shown that …

Despite improvements in pharmacotherapy, morbidity and mortality rates in community-
based populations with chronic heart failure still remain high. The increase in medical …

During the last decade we experienced a surge in the number of glucose lowering agents
that can be used to treat patients with type 2 diabetes. Especially important are the …

Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors have been shown to
significantly reduce hospitalization for heart failure (HHF) and cardiovascular (CV) mortality …

Type 2 diabetes mellitus (T2DM) is a complex multifactorial disease causing the
development of a large range of cardiovascular (CV) complications. Lifestyle changes and …

Recent evidence relating to the impact of COVID-19 on people with diabetes is limited but
continues to emerge. COVID-19 pneumonia is a newly identified illness spreading rapidly …

Abstract In the pandemic “Corona Virus Disease 2019”(COVID-19) people with diabetes
have a high risk to require ICU admission. The management of diabetes in Intensive Care …